Sentiment-Signal
21,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
27.8
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Scholar Rock Holding Corp |
|---|---|
| Ticker | SRRK |
| CIK | 0001727196 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 80706p103 |
|---|---|
| ISIN | US80706P1030 |
| Typ | Common Stock |
| Marktkapitalisierung | 5,52 Mrd. USD |
| Beta | 0,69 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -377,939,000 | -3.29 | 404,272,000 | 245,488,000 |
| 2025-09-30 | 10-Q | 0 | -102,220,000 | -0.90 | 411,718,000 | 244,995,000 |
| 2025-06-30 | 10-Q | 0 | -110,031,000 | -0.98 | 340,045,000 | 233,293,000 |
| 2025-03-31 | 10-Q | -74,723,000 | -0.67 | 407,553,000 | 312,333,000 | |
| 2024-12-31 | 10-K | -246,294,000 | -2.47 | 474,922,000 | 368,634,000 | |
| 2024-09-30 | 10-Q | -64,479,000 | -0.66 | 179,133,000 | 79,196,000 | |
| 2024-06-30 | 10-Q | -58,508,000 | -0.60 | 226,865,000 | 133,620,000 | |
| 2024-03-31 | 10-Q | -56,853,000 | -0.59 | 267,285,000 | 182,773,000 | |
| 2023-12-31 | 10-K | -165,789,000 | -1.99 | 311,035,000 | 225,218,000 | |
| 2023-09-30 | 10-Q | -42,359,000 | -0.53 | 250,689,000 | 167,665,000 | |
| 2023-06-30 | 10-Q | -37,925,000 | -0.47 | 284,900,000 | 202,501,000 | |
| 2023-03-31 | 10-Q | -39,379,000 | -0.49 | 314,721,000 | 228,653,000 | |
| 2022-12-31 | 10-K | 33,193,000 | -134,502,000 | -2.26 | 358,168,000 | 260,235,000 |
| 2022-09-30 | 10-Q | 33,193,000 | -43,297,000 | -0.55 | 390,303,000 | 293,265,000 |
| 2022-06-30 | 10-Q | 33,193,000 | -44,000,000 | -1.06 | 424,128,000 | 329,507,000 |
| 2022-03-31 | 10-Q | 33,193,000 | -7,950,000 | -0.21 | 265,977,000 | 171,316,000 |
| 2021-12-31 | 10-K | 18,816,000 | -131,799,000 | -3.59 | 304,445,000 | 172,074,000 |
| 2021-09-30 | 10-Q | 5,464,000 | -37,507,000 | -1.02 | 298,389,000 | 187,260,000 |
| 2021-06-30 | 10-Q | 4,595,000 | -30,707,000 | -0.84 | 332,051,000 | 216,656,000 |
| 2021-03-31 | 10-Q | 4,708,000 | -27,671,000 | -0.76 | 360,586,000 | 240,540,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| AMI ASSET MANAGEMENT CORP | 29,476 | 0 | 29,476 | 1,298,418 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Hallal David | Director, Officer, Chief Executive Officer | Open Market Sale | -30,615 | 49.57 | -1,517,723.32 | -167,5% | |
| 2026-04-16 | Vaishnaw Akshay | Director, Officer, President of R&D | Open Market Sale | -12,246 | 49.57 | -607,089.33 | -67,0% | |
| 2026-04-16 | Sinha Vikas | Officer, Chief Financial Officer | Open Market Sale | -10,410 | 49.57 | -516,070.55 | -56,9% | |
| 2026-04-16 | Woods Keith | Officer, Chief Operating Officer | Open Market Sale | -10,220 | 49.57 | -506,651.39 | -55,9% | |
| 2026-02-17 | Ho Junlin | Officer, GENERAL COUNSEL | Open Market Sale | -9,580 | 46.53 | -445,740.16 | -49,2% | |
| 2026-02-17 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7,989 | 46.53 | -371,713.79 | -41,0% | |
| 2026-02-17 | Parlavecchio Caryn | Officer, CHRO | Open Market Sale | -9,035 | 46.53 | -420,382.29 | -46,4% | |
| 2026-02-17 | Marantz Jing L. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -4,157 | 46.53 | -193,417.73 | -21,3% | |
| 2026-01-22 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12,779 | 46.85 | -598,748.54 | -66,1% | |
| 2026-01-22 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -2,119 | 45.87 | -97,188.99 | -10,7% | |
| 2026-01-16 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -8,406 | 44.48 | -373,879.55 | -41,3% | |
| 2026-01-16 | Ho Junlin | Officer, GENERAL COUNSEL | Open Market Sale | -8,016 | 44.48 | -356,533.24 | -39,3% | |
| 2026-01-16 | Marantz Jing L. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,798 | 44.48 | -257,881.70 | -28,5% | |
| 2026-01-16 | Parlavecchio Caryn | Officer, CHRO | Open Market Sale | -6,600 | 44.48 | -293,552.82 | -32,4% | |
| 2026-01-14 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -13,112 | 45.20 | -592,611.26 | -65,4% | |
| 2026-01-13 | Sinha Vikas | Officer, Chief Financial Officer | Open Market Sale | -16,755 | 42.70 | -715,438.50 | -78,9% | |
| 2026-01-13 | Hallal David | Director, Officer, Chief Executive Officer | Open Market Sale | -57,450 | 42.70 | -2,453,115.00 | -270,7% | |
| 2026-01-13 | Woods Keith | Officer, Chief Operating Officer | Open Market Sale | -16,746 | 42.70 | -715,054.20 | -78,9% | |
| 2026-01-13 | Vaishnaw Akshay | Director, Officer, President of R&D | Open Market Sale | -20,438 | 42.70 | -872,702.60 | -96,3% | |
| 2025-12-16 | Peng Katie | Director | Open Market Sale | -726 | 43.88 | -31,854.05 | -3,5% | |
| 2025-12-16 | Peng Katie | Director | Open Market Sale | -280 | 44.63 | -12,497.63 | -1,4% | |
| 2025-12-04 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -136,462 | 45.21 | -6,169,788.18 | -680,8% | |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 12,796 | 39.31 | 503,010.76 | +55,5% | |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 4,403 | 40.97 | 180,390.91 | +19,9% | |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 12,400 | 40.18 | 498,232.00 | +55,0% | |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 13,748 | 39.52 | 543,320.96 | +60,0% | |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 80,863 | 38.68 | 3,127,780.84 | +345,1% | |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 18,414 | 37.89 | 697,706.46 | +77,0% | |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 319,700 | 37.42 | 11,963,174.00 | +1320,1% | |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 56,703 | 36.74 | 2,083,268.22 | +229,9% | |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 11,011 | 35.61 | 392,101.71 | +43,3% | |
| 2025-09-22 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -3,353 | 30.67 | -102,846.23 | -11,3% | |
| 2025-09-16 | Peng Katie | Director | Open Market Sale | -76 | 33.20 | -2,522.92 | -0,3% | |
| 2025-09-16 | Peng Katie | Director | Open Market Sale | -930 | 32.48 | -30,202.77 | -3,3% | |
| 2025-09-16 | Qatanani Mo | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -3,178 | 33.52 | -106,526.56 | -11,8% | |
| 2025-06-16 | Peng Katie | Director | Open Market Sale | -2,977 | 31.96 | -95,131.82 | -10,5% | |
| 2025-06-16 | Peng Katie | Director | Open Market Sale | -54 | 32.53 | -1,756.56 | -0,2% | |
| 2025-05-29 | Burow Kristina | Director | Open Market Sale | -4,400 | 29.83 | -131,268.72 | -14,5% | |
| 2025-05-29 | Vaishnaw Akshay | Director, Officer, President of R&D | Open Market Sale | -5,130 | 29.63 | -152,000.36 | -16,8% | |
| 2025-05-29 | Vaishnaw Akshay | Director, Officer, President of R&D | Open Market Sale | -1,620 | 30.01 | -48,611.66 | -5,4% | |
| 2025-05-29 | Reed Joshua | Director | Open Market Sale | -4,900 | 29.68 | -145,440.82 | -16,0% | |
| 2025-05-29 | Reed Joshua | Director | Open Market Sale | -500 | 30.04 | -15,021.75 | -1,7% | |
| 2025-05-29 | Burow Kristina | Director | Open Market Sale | -1,000 | 29.24 | -29,241.90 | -3,2% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| AMI ASSET MANAGEMENT CORP | 29,476 | 1,298,418 | 100.00 |